L42. Morbidity in patients with ANCA-associated vasculitis

Presse Medicale

Volumn 42, Issue 4 PART2, 2013, Pages 612-616

  Harper, Lorraine ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; INFLUENZA VACCINE; MESNA; PNEUMOCOCCUS VACCINE; PREDNISOLONE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; AVASCULAR NECROSIS; BONE DENSITY; BONE MARROW SUPPRESSION; CANCER RISK; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL (TOPIC); CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIPHTHERIA; DISEASE ACTIVITY; EAR DISEASE; HAIR LOSS; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; INFERTILITY; INFLUENZA; KIDNEY FAILURE; LETTER; LEUKOPENIA; LUNG FIBROSIS; MORBIDITY; NOSE DISEASE; OPPORTUNISTIC INFECTION; OSTEOPENIA; PERTUSSIS; PNEUMOCYSTIS PNEUMONIA; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL RATE; TETANUS; THROAT DISEASE; VENOUS THROMBOEMBOLISM;

EID: 84875596945     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.01.040     Document Type: Letter

References (60)

1. Mukhtyar C., Flossmann O., Hellmich B., Bacon P., Cid M., Cohen-Tervaert J.W., et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008, 67(7):1004-1010. [Epub 2007 Oct 2].
2. Flossmann O., Berden A., de Groot K., Hagen C., Harper L., Heijl C., et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011, 70(3):488-494.
3. Hogan S., Nachman P., Wilkman A., Jennette J., Falk R. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996, 7:23-32.
4. Reinhold-Keller E., Beuge N., Latza U., De Groot K., Rudert H., Nolle B., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in155 patients. Arthritis Rheum 2000, 43:1021-1032.
5. Xing G.Q., Chen M., Liu G., Zheng X., E J., Zhao M.H. Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis. J Clin Immunol 2010, 30(1):144-156.
6. Booth A.D., Almond M.K., Burns A., Ellis P., Gaskin G., Neild G.H., et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003, 41(4):776-784.
7. Nachman P., Hogan S., Jennette J., Falk R. Treatment response and relapse in ANCA-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996, 7:33.
8. Day C.J., Howie A.J., Nightingale P., Shabir S., Adu D., Savage C.O., et al. Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: quantitative histomorphometric assessment and serum creatinine. Am J Kidney Dis 2010, 55(2):250-258.
9. de Lind van Wijngaarden R.A., Hauer H.A., Wolterbeek R., Jayne D.R., Gaskin G., Rasmussen N., et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006, 17(8):2264-2274.
10. de Lind van Wijngaarden R.A., Hauer H.A., Wolterbeek R., Jayne D.R., Gaskin G., Rasmussen N., et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol 2007, 18(7):2189-2197.
11. Laudien M., Lamprecht P., Hedderich J., Holle J., Ambrosch P. Olfactory dysfunction in Wegener's granulomatosis. Rhinology 2009, 47(3):254-259.
12. Arulkumaran N., Periselneris N., Gaskin G., Strickland N., Ind P.W., Pusey C.D., et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford) 2011, 50(11):2035-2043.
13. Hervier B., Pagnoux C., Agard C., Haroche J., Amoura Z., Guillevin L., et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis 2009, 68(3):404-407.
14. Merkel P.A., Lo G.H., Holbrook J.T., Tibbs A.K., Allen N.B., Davis J.C., et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005, 142(8):620-626.
15. Stassen P.M., Derks R.P., Kallenberg C.G., Stegeman C.A. Venous thromboembolism in ANCA-associated vasculitis-incidence and risk factors. Rheumatology (Oxford) 2008, 47(4):530-534.
16. Berden A.E., Nolan S.L., Morris H.L., Bertina R.M., Erasmus D.D., Hagen E.C., et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. J Am Soc Nephrol 2010, 21(12):2169-2179.
17. Basu N., Jones G.T., Fluck N., MacDonald A.G., Pang D., Dospinescu P., et al. Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology (Oxford) 2010, 49(7):1383-1390.
18. Herlyn K., Seo P., Hellmich B., Reimer J., Merkel P.A. Patient reported outcome assessment in primary systemic vasculiti with a new instrument provides a unique perspective. APMIS 2009, 117(Suppl. 127):149.
19. Faurschou M., Sigaard L., Bjorner J.B., Baslund B. Impaired health-related quality of life in patients treated for Wegener's granulomatosis. J Rheumatol 2010, 37(10):2081-2085.
20. Little M.A., Nightingale P., Verburgh C.A., Hauser T., De Groot K., Savage C., et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010, 69:1036-1043.
21. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Int Med 1992, 116:488-498.
22. Wung P., Holbrook J., Hoffman G., Tibbs A., Specks U., Min Y.I., et al. Risk factors for Herpes Zoster in immunocompromised patients: experience from the Wegener's granulomatosis etanercept trial. Kidney Blood Press Res 2005, 28:175.
23. Ognibene F.P., Shelhamer J.H., Hoffman G.S., Kerr G.S., Reda D., Fauci A.S., et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995, 151(3 Pt 1):795-799.
24. Ward M.M., Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999, 42(4):780-789.
25. Falagas M.E., Manta K.G., Betsi G.I., Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 2007, 26(5):663-670. [Epub 2006 Dec 21].
26. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363(3):211-220.
27. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363(3):221-232.
28. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009, 68(1):25-32.
29. Gottenberg J.E., Ravaud P., Bardin T., Cacoub P., Cantagrel A., Combe B., et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010, 62(9):2625-2632.
30. Major E.O. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010, 61:35-47.
31. Harper L., Savage C.O. ANCA-associated renal vasculitis at the end of the twentieth century-a disease of older patients. Rheumatology (Oxford) 2005, 44(4):495-501.
32. Charlier C., Henegar C., Launay O., Pagnoux C., Berezne A., Bienvenu B., et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 2009, 68(5):658-663.
33. Mukhtyar C., Guillevin L., Cid M.C., Dasgupta B., de Groot K., Gross W., et al. EULAR Recommendations for the management of primary small and medium vessel vasculitis. Annals Rheum Dis 2009, 68:310-317.
34. Hellmich B., Schnabel A., Gross W. G-CSF treatment for cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis. Arthritis Rheum 1999, 42:1752-1756.
35. Freeley S.J., Coughlan A.M., Popat R.J., Dunn-Walters D.K., Robson M.G. Granulocyte colony stimulating factor exacerbates antineutrophil cytoplasmic antibody vasculitis. Ann Rheum Dis 2012, 10.1136/annrheumdis-2012-202160.
36. Stassen P.M., Sanders J.S., Kallenberg C.G., Stegeman C.A. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2008, 23(2):654-658. [Epub 2007 Oct 2].
37. Marchand-Janssen C., Loulergue P., Mouthon L., Mahr A., Blanche P., Deforges L., et al. Patients with systemic inflammatory and autoimmune diseases are at risk of vaccine-preventable illnesses. Rheumatology (Oxford) 2011, 50(6):1099-1105.
38. Bearden C.M., Agarwal A., Book B.K., Vieira C.A., Sidner R.A., Ochs H.D., et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005, 5(1):50-57.
39. Boomsma M.M., Stegeman C.A., Kramer A.B., Karsijns M., Piers D.A., Tervaert J.W. Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study. Osteoporos Int 2002, 13(1):74-82.
40. Guillevin L., Durand-Gasselin B., Cevallos R., Gayraud M., Lhote F., Callard P., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999, 42(3):421-430.
41. Guillevin L., Cohen P., Mahr A., Arene J.P., Mouthon L., Puechal X., et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003, 49(1):93-100.
42. Le Guenno G., Mahr A., Pagnoux C., Dhote R., Guillevin L. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011, 63(5):1435-1445.
43. Talar-Williams C., Hijazi Y., Walther M., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann Intern Med 1996, 124:477.
44. Huong D.L., Amoura Z., Duhaut P., Sbai A., Costedoat N., Wechsler B., et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 2002, 29(12):2571-2576.
45. Park M.C., Park Y.B., Jung S.Y., Chung I.H., Choi K.H., Lee S.K. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004, 13(8):569-574.
46. Dooley M.A., Nair R. Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease. Nat Clin Pract Rheumatol 2008, 4(5):250-257.
47. Pendse S., Ginsburg E., Singh A.K. Strategies for preservation of ovarian and testicular function after immunosuppression. Am J Kidney Dis 2004, 43(5):772-781.
48. Lapraik C., Watts R., Bacon P., Carruthers D., Chakravarty K., D'Cruz D., et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007, 46(10):1615-1616. [Epub 2007 Sep 5].
49. Knight A., Askling J., Granath F., Sparen P., Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004, 63(10):1307-1311.
50. Westman K.W., Bygren P.G., Olsson H., Ranstam J., Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998, 9(5):842-852.
51. Faurschou M., Sorensen I.J., Mellemkjaer L., Loft A.G., Thomsen B.S., Tvede N., et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008, 35(1):100-105. [Epub 2007 Oct 15].
52. Heijl C., Harper L., Flossmann O., Stucker I., Scott D.G., Watts R.A., et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011, 70(8):1415-1421.
53. Morgan M., Turnbull J., Selemet U., Nightingale P., Ferro C., Harper L. Increased incidence of cardiovascular events in patients with ANCA-associated vasculitis: matched pair cohort study. Arthritis Rheum 2009, 60:3493-3500.
54. Faurschou M., Mellemkjaer L., Sorensen I.J., Svalgaard Thomsen B., Dreyer L., Baslund B. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009, 60(4):1187-1192.
55. Goedendorp M.M., Gielissen M.F., Verhagen C.A., Bleijenberg G. Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 2009, 1:CD006953.
56. Suppiah R., Judge A., Batra R., Flossmann O., Harper L., Hoglund P., et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res 2011, 63(4):588-596.
57. Booth A.D., Wallace S., McEniery C.M., Yasmin, Brown J., Jayne D.R., et al. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 2004, 50(2):581-588.
58. de Leeuw K., Sanders J.S., Stegeman C., Smit A., Kallenberg C.G., Bijl M. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005, 64(5):753-759. [Epub 2004 Sep 16].
59. Domsic R., Maksimowicz-McKinnon K., Manzi S. Prevention of cardiovascular disease in patients with rheumatic diseases. Best Pract Res Clin Rheumatol 2006, 20(4):741-756.
60. Zonana-Nacach A., Barr S.G., Magder L.S., Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000, 43(8):1801-1808.